Kinga Bercsenyi, PhD

Here’s an interesting publication detailing how trial efficiency can reshape early-stage development in #biotech... In Phase I studies, every decision affects the development pathway, making trial design and timing critical. By introducing flexibility into these early phases, clinical teams can meet complex study demands without compromising on speed or quality—a balance essential in today’s fast-paced therapeutic field. With streamlined processes, from recruitment through data collection, biotech R&D professionals can better allocate resources, achieve reliable results, and move confidently toward later stages of development. #BiotechR&D #BioTech #BioPharm #EarlyStageDevelopment #ClinicalTrials #TrialEfficiency #DrugDevelopment

3

You can still register for this webinar, demonstrating the Quantum-Aided Drug Design (#QuADD) platform.

10

🌟 NEW CASE STUDY 🌟 👩‍🔬 Forensic researchers at King's College London are harnessing cutting-edge equipment from Thermo Fisher Scientific to delve into critical #research concerning the detection of #drugs in human samples with suspected acute drug #toxicity. 💡 This partnership, involving the university, Guy's and St Thomas'​ NHS Foundation Trust, and Thermo Fisher Scientific, aims to revolutionize the analysis of #blood samples from patients presenting with acute drug toxicity in the #emergency department (#ED). 🏥 The potential impact? Faster, more precise #detection and #quantification methods for acute drug toxicity that could become routine in hospitals, ultimately improving health outcomes for individuals in the emergency department. https://lnkd.in/enM4VPDb Edward Goucher | Alexandra Graham | Vincenzo Abbate | Paul Dargan

62

1 Comment

Missed #LondonCalling and need a summary of what's new for Oxford Nanopore Technologies? 👨‍💻 Huge set of software releases. New Transformer models increase simplex accuracy from Q24.5 in sup-v4.3.0 to Q26.0 in sup-v5.0.0. 👩‍💻 Integrated HERRO - Q50 pre-assembly simplex reads corrected with ‘dorado correct’ using Herro. 🔬 New Modifications - RNA m6A extended to all contexts, RNA PseudoU models all contexts, and DNA 4mC. 🖥 NEW MinION Mk1D - Closed Early Access devices will begin shipping in July. 💻 ElysION Automation is moving to Early Access - DNA extraction to sequence data. - Plus sneak peak into future instruments. Watch the tech talk or read the full summary in the link below: https://lnkd.in/gUqU8HwD

21

3 Comments

🥂 Celebrating another UKB-PPP publication. Changing the world 👨🏽‍⚕️ 🌍! 📢 Check out the numbers of findings 👇🏽 👹 With all the scary bots, deep fakes, and other AI-related craziness, it’s wonderful to see cancer researchers using AI and machine learning for good. 😇 🖥 An in-silico interrogation of the UKB-PPP dataset by Papier et al. identified predictive risk markers for 19 different forms of cancer. Although the findings are limited to univariate protein-cancer associations with moderate predictive values, the headline figures have caught the attention of the mainstream media - 618 protein-cancer associations, corresponding to 371 different proteins, where 107 retained significance >7 years prior to diagnosis. The research, published in Nature Communications, delves into the investigation of potential observational and genetic protein-cancer risk associations using data from the UK Biobank. They discovered multiple blood protein-cancer risk associations, some detectable more than seven years before cancer diagnosis. This groundbreaking work highlights the potential role of these proteins in cancer development and signifies a significant step towards risk stratification and early diagnosis. For further information: DOI: 10.1038/s41467-024-48017-6 https://lnkd.in/e2ysQafb #CancerResearch #AI #MachineLearning #ProteinCancerAssociations #UKBiobank #NatureCommunications

12

Did you miss our webinar yesterday 😱? No worries! You can still watch the recording of the "Find your star. Delivering business value with Quantum-Aided Drug Design" webinar here: https://lnkd.in/gQEGAUVd

10

https://lnkd.in/eWsz7CcU With over 60 references, The Neospora Antibody Test Kit from VMRD, Inc. and available from 2BScientific Ltd. employs a competitive ELISA technique to detect the presence of Neospora caninum antibodies in serum samples from cattle. 🐝 Exceptional Precision: Evidenced through sensitivity and specificity assessments, ensuring dependable identification of both positive and negative sera. 🐝 Distinct Discrimination: 5% of sera registered within ±5% of the cut-off value, underscoring exact differentiation between positive and negative samples. 🐝 Streamlined Screening: Streamlines the examination of extensive sample sets, as evidenced by the analysis of 4,323 sera with unknown serologic statuses. 🐝 Robust Confidence: Minimal overlap near the cut-off value inspires assurance in the kit's accuracy. For your own research reagents, get in contact at [email protected] with any queries about this ELISA, our products, or anything concerning life science! #petwelfare #neospora #hereforyou

5

The white paper in the AAPS Journal by Amanda Hays, Mark Wissel, et al. is a comprehensive and detailed review, offering a wealth of well-thought-out recommendations. Its thoroughness and relevance to advancing Cell and Gene Therapeutics for development and approval will undoubtedly leave you feeling informed and confident in its content. It stands out for its unique contribution to Cell and Gene Therapeutics. It addresses the lack of information and guidelines for qPCR and dPCR. It brings together cross-industry conversations and an American Association of Pharmaceutical Scientists 2024 working group to fill these gaps. They acknowledge that the modalities for Cell and Gene Therapy have advanced rapidly and describe the inherent complexity that can overwhelm the method development and validation of these therapeutics and complicate the efficacy and safety of these therapeutics, which is critical. The white paper's practical approach is a testament to its value. It provides theoretical insights and offers a clear roadmap for implementing Cell and Gene Therapy using qPCR and dPCR as the bioanalytical platforms, as depicted in Figure 1. The emphasis on designing and validating assays to fit their intended purpose is a powerful tool that can directly support therapeutic development, making you feel empowered and capable of implementing these recommendations. The two central assay designs and development that I found informative were the design and selection of primers and probes for a bioanalytical PCR assay, which the paper goes into detail on, and designing single-nucleotide sequences (singleplex reactions) or multiple-nucleotide sequences (multiple reactions). They stated that the qPCR efficiency in multiplex vs. singleplex should be 90-110% with similar curve slopes, similar detection limits (LOD), and similar precision and accuracy performance. For multiplexing in dPCR, they say to ensure that the droplets/partitions can be distinguished between the two targets and that the fluorophores do not compete. In Table 1(pg. 8), they describe in excellent detail the advantages of qPCR and dPCR for Cell and Gene Therapy applications. They also propose evaluating the assay reagent and platform changes on a case-by-case basis and suggest that they be determined based on the context of use (COU). Lastly, the authors summarize the relevant publications and guidance documents on PCR validations in Table 4 (pages 15-21). This is a well-done evaluation of the different validation criteria. This white paper is a must-read for those involved in Cell and Gene Therapeutics development and validation. It's a valuable resource that directly addresses our needs and can significantly enhance our work. Please download the paper here: https://lnkd.in/eVVMSXvp

72

2 Comments

The U.K. Department for Business and Trade (DBT) has produced the Genomics Spotlight 2024 to showcase the UK’s expertise in genomics and latest developments that make the UK a hub for genomics business and investment, and we are delighted that C4X Discovery Ltd's genetics stratification platform, PatientSeek, has been included. The document highlights both the export potential of UK companies, as well as the investment potential across the wider NHS infrastructure and research institutes. This is a reminder of the world leading genomics capabilities we have in the UK, from the NHS Genomic Medicine Service which is the first national healthcare system in the world to offer Whole Genome Sequencing (WGS) as part of routine care, to world leading institutions and research cohorts, to the ever-expanding innovation of UK small businesses - the UK has a lot to offer. https://lnkd.in/eJKf2B3b

11

2 Comments

The first few patients are always the most critical in the life cycle of a cell therapy product. One gets a fundamental understanding about the product's safety profile, the surgeon's ability to deliver it without major side effects and finally and most importantly, how the cells interact with the diseased retina. The first principles knowledge arrived at over the last few weeks has enhanced our confidence in the eventual ability of this product to potentially transform patient lives. Download the full press release including what our Principal Investigators think from the link below !

154

46 Comments

Oxford Nanopore announces breakthrough technology performance to deliver complete human genome assemblies and richer multiomic data in London Calling tech update Oxford Nanopore Chief Technology, Innovation and Product Officer Clive G Brown announced breakthrough performance data and new platform updates in his technology update at the company’s annual London Calling conference, held between 21 and 24 May 2024. The talk launched the nanopore-only telomere-to-telomere (T2T) genome assembly product bundle, making this breakthrough method more accessible. In addition, Clive showed a glimpse of what may be possible in the future with the sequencing of a whole T2T yeast chromosome in a single read for the first time. Further improvements in direct RNA sequencing accuracy and yield, and pipelines for ultra-high output sequencing, including a potential route to a 15-minute human genome, were shared. Building on the distinctive advantages of the Oxford Nanopore platform, these advancements deliver highly accurate, information-rich data, faster insights, at any scale for both DNA and RNA sequencing applications. Oxford Nanopore’s technology continues to evolve to meet the growing demand for accessible, real-time analysis and open new possibilities in research, clinical and industrial settings. https://lnkd.in/gt5uifM5

10

VIDEO throwback - London Calling 2023: London Calling 2023: Single-cell long-read RNA sequencing reveals complex heterogeneity in leukaemia While introduction of novel targeted inhibitors has markedly altered the therapeutic options for treating patients with blood cancers, relapses due to acquired resistance after initial response remain a major problem. To delineate drug resistance, we applied a novel single-cell omics approach on samples from patients with progressive leukaemia who failed therapy with a targeted agent. Combining short-read with long-read targeted and whole-transcriptome sequencing identified mutations and alternative transcripts in specific sub-clones of the tumour at relapse. Thus, our single-cell integration of short-read and full-length RNA-seq provides novel insights into how complex tumour heterogeneity evolves upon acquisition of drug resistance. https://lnkd.in/gN6f2qQy

3

Register for this webinar to learn about different methods for adventitious agent testing and how next generation sequencing is enhancing safety of biologicals. #virusidentification #safety #bioassays #ngs #CGT

7

The transition between discovery #proteomics and #clinical testing requires establishing standardization, robustness, sensitivity, specificity and absolute quantitation in the final test. Here, a collaboration between Max Planck Institute, Thermo Fisher Scientific and Absea Biotech showcasing a smooth journey from discovery to implementation, utilizing top-end MS (Orbitrap Astral) for the early phase, and a hybrid MS (Stellar MS) for the final test. The common element is standardized, robust chromatography with Evosep One: #standardization ==> a smooth transition, with confident characterization of the #biomarker peptides between discovery and clinical testing, even when discovery is done in one continent and final test in another #robustness ==> is the key factor for a successful implementation in a clinical setting where hundreds of samples per day are required #reproducibility ==> assures avoidance of false negatives due to RT shift, https://lnkd.in/ePYsyXxt

23

Want to catch bacterial contamination early in your CHO cell cultures? Aber Instruments Ltd's webinar (link below!) explores how conductivity & dielectric spectroscopy can help with real-time monitoring & process automation. https://lnkd.in/eQPxdiGj #WebinarAlert #bioprocess #biotechnology #ProcessAutomation #CellCulture #ContaminationDetection #learning

4

I wanted to share this fascinating article recently published in the New Yorker: How Machines Learned to Discover Drugs. It provides a comprehensive overview of the advances made in AI-led drug discovery since the mid-2000s, showing how far our industry has come with integrating AI into conventional methods of discovering new drugs.     Three takeaways that struck me as I was reading: (1) AI helps to mitigate "Erooms's Law" – a term coined to describe how drug discovery is becoming slower and more expensive over time despite technology advancing. With its ability to efficiently analyse massive datasets, AI can be used to identify promising drug candidates and potentially reduce trial costs.    (2) AI has the potential to find new applications for existing medications, allowing us to expand the range of drugs available. Notably, the article highlights the discovery of Halicin, originally a diabetes drug, that was found to elicit broad-spectrum antibiotic properties and is currently undergoing further clinical trials thanks to the application of AI.   (3) Whilst AI shows immense promise, human expertise and judgement remains essential for successful drug development. Here at Exscientia, our talented teams play an essential part in moving towards closing the loop between virtual drug design and experimentation.     This article makes me excited for the future of AI. What do you think has been the biggest success in AI drug discovery so far? You can read more here: https://lnkd.in/eaM5Zs_i

129

6 Comments

🚀 Announcing Macrogen’s Latest Breakthrough in Pharmacogenetics! 🚀 We are thrilled to share our recent research on pharmacogenetic variation, conducted in collaboration with the 1000 Genomes Project. Using whole-genome sequencing, we analyzed 58 essential pharmacogenes involved in drug absorption, distribution, metabolism, and excretion across diverse global populations. 🌍🔬 Employing the PyPGx tool, we identified and characterized various structural variants—such as gene deletions, duplications, and hybrids—uncovering both established and novel variants. This study offers a detailed profile of population-level star alleles and phenotype frequencies, providing insights that could enhance precision medicine and advance drug therapies tailored to individual genetic profiles. 💡🧬 Our findings demonstrate the increasing utility of cost-effective whole-genome sequencing for pharmacogenomic genotyping, refining drug selection and dosage, reducing adverse drug reactions, and optimizing therapeutic outcomes across diverse populations. 💊✨ Stay tuned as we continue to push the boundaries of pharmacogenomic research, contributing to the evolution of more personalized and equitable healthcare solutions. 🌟📈 Please check the link below for more details: https://rdcu.be/dYqgw 📞 Contact Us Order page: https://dna.macrogen.com/ Email: [email protected] #Macrogen #Pharmacogenetics #PrecisionMedicine #WholeGenomeSequencing #DrugTherapies #GlobalHealth #GenomicsResearch

3

Want glycan analysis method expertise? In this video, our Navin Rauniyar discusses his recently published study. Check it out! #proteinsciences #protein #groundbreaking #biotech #CDMO #analyticaldevelopment #glycananalysis

42

Benchmarking metabolomics software just got more precise: this novel simulated and experimental LC-MS data sets reveal that MVAPACK outperforms existing tools, offering unparalleled clarity in both NMR and MS data analysis. #Metabolomics #DataScience #HealthcareInnovation https://lnkd.in/ggBb-XEe

4